疏血通联合阿托伐他汀治疗急性脑梗死患者的效果

Effects of Shuxuetong combined with Atorvastatin in treatment of patients with acute cerebral infarction

目的:观察疏血通联合阿托伐他汀治疗急性脑梗死(ACI)患者的效果。方法:选取2019年10月至2021年10月该院收治的90例ACI患者进行前瞻性研究,采用随机数字表法分为对照组和观察组各45例。两组均予以常规治疗,在此基础上,对照组采用阿托伐他汀治疗,观察组在对照组基础上联合疏血通治疗,比较两组临床疗效、治疗前后颈动脉内中膜厚度(CIMT)、斑块面积、斑块数量、神经功能缺损[美国国立卫生研究院卒中量表(NIHSS)]评分、血清学指标[白细胞介素-6(IL-6)、可溶性细胞间黏附分子1(sICAM-1)、肿瘤坏死因子-α(TNF-α)]水平、血液流变学指标水平、血脂指标水平和治疗期间不良反应发生率。结果:观察组治疗总有效率为95.56%(43/45),高于对照组的80.00%(36/45),差异有统计学意义(P<0.05);治疗后,观察组CIMT、斑块面积均小于对照组,斑块数量少于对照组,差异有统计学意义(P<0.05);治疗后,观察组NIHSS评分及IL-6、sICAM-1、TNF-α水平均低于对照组,差异有统计学意义(P<0.05);治疗后,观察组血浆黏度、全血高切黏度、全血低切黏度、三酰甘油、总胆固醇和高密度脂蛋白胆固醇水平均低于对照组,低密度脂蛋白胆固醇水平高于对照组,差异有统计学意义(P<0.05)。结论:疏血通联合阿托伐他汀治疗ACI患者可提高治疗总有效率,缩小CIMT和斑块面积,减少斑块数量,改善血脂指标水平,降低血液流变学指标水平、血清学指标水平和NIHSS评分,效果优于单纯阿托伐他汀治疗。

Objective:To observe effects of Shuxuetong combined with Atorvastatin in treatment of patients with acute cerebral infarction(ACI).Methods:A prospective study was conducted on 90 ACI patients admitted to the hospital from October 2019 to October 2021.They were divided into control group and observation group by using the random number table method,45 cases in each.Both groups were given routine treatment.On this basis,the control group was treated with Atorvastatin,while the observation group was treated with Shuxuetong on the basis of that of the control group.The clinical efficacy,the carotid intima-media thickness(CIMT),the plaque area,the plaque number,the neurological deficit[national institutes of health stroke scale(NIHSS)]score,the serological indicator levels[interleukin-6(IL-6),human soluble intercellular adhesion molecule 1(sICAM-1),tumor necrosis factor-α(TNF-α)],the hemorheology index levels,the blood lipid index levels,and incidence of adverse reactions during treatment were compared between the two groups.Results:The total effective rate of treatment in the observation group was 95.56%(43/45),which was higher than 80.00%(36/45)in the control group,and the difference was statistically significant(P<0.05).After the treatment,the CIMT and the plaque area of the observation group were smaller than those of the control group,the plaque number was less than that of the control group,and the differences were statistically significant(P<0.05).After the treatment,the NIHSS score and the levels of IL-6,sICAM-1 and TNF-αin the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).Further,after the treatment,the levels of plasma viscosity,whole blood high shear viscosity,whole blood low shear viscosity,triglyceride,total cholesterol and high density lipoprotein cholesterol in the observation group were lower than those in the control group,the level of low density lipoprotein cholesterol was higher than that in the control group,and the differences were statistically significant(P<0.05).Conclusions:Shuxuetong combined with Atorvastatin in the treatment of the ACI patients can improve the total effective rate of treatment,reduce the CIMT and the plaque area,reduce the plaque number,improve the levels of blood lipid indexes,and reduce the levels of hemorheology indexes and serological indexes as well as the NIHSS scores.Moreover,it is superior to single Atorvastatin treatment.